KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBT (2016 - 2026)

TherapeuticsMD filings provide 17 years of EBT readings, the most recent being $103000.0 for Q1 2026.

  • On a quarterly basis, EBT rose 115.42% to $103000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $118000.0, a 105.36% increase, with the full-year FY2025 number at -$653000.0, up 72.13% from a year prior.
  • EBT hit $103000.0 in Q1 2026 for TherapeuticsMD, up from -$580000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $48.5 million in Q4 2022 to a low of -$17.9 million in Q1 2022.
  • Median EBT over the past 5 years was -$809000.0 (2024), compared with a mean of -$562411.8.
  • The widest YoY moves for EBT: up 151.9% in 2025, down 798.8% in 2025.
  • TherapeuticsMD's EBT stood at $48.5 million in 2022, then tumbled by 103.27% to -$1.6 million in 2023, then skyrocketed by 105.24% to $83000.0 in 2024, then crashed by 798.8% to -$580000.0 in 2025, then skyrocketed by 117.76% to $103000.0 in 2026.
  • The last three reported values for EBT were $103000.0 (Q1 2026), -$580000.0 (Q4 2025), and $50000.0 (Q3 2025) per Business Quant data.